Accelerated Withdrawal in Action: The Avastin Hearing Process
This article was originally published in RPM Report
Executive Summary
The June hearing on the status of Genentech’s metastatic breast cancer indication for Avastin will focus on a long list of substantive disagreements about the data. But any sponsor interested in the future of the accelerated approval process should study the back-and-forth in the hearing process itself.